Drug intelligence / Profile preview

PRO-PSC-001

Development stage: Preclinical
Lead developer: Prodigy Biotech
Modality: Antibody-Based Therapeutics

Overview

PRO-PSC-001 is an investigational IgY (immunoglobulin Y) antibody therapeutic being developed by Prodigy Biotech for the treatment of Primary Sclerosing Cholangitis (PSC). As part of Prodigy's core technology platform, PRO-PSC-001 is designed to selectively target and neutralize specific microbial components or toxins in the gastrointestinal tract that contribute to the pathogenesis of PSC. This approach aims to modulate the gut-liver axis to reduce biliary inflammation and fibrosis. The candidate is currently in the preclinical stage of development.

Beyond the preview

Go deeper on PRO-PSC-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRO-PSC-001.

Explore the full profile